Success Metrics

Clinical Success Rate
76.5%

Based on 13 completed trials

Completion Rate
76%(13/17)
Active Trials
0(0%)
Results Posted
85%(11 trials)
Terminated
4(22%)

Phase Distribution

Ph phase_2
7
39%
Ph phase_3
3
17%
Ph phase_1
8
44%

Phase Distribution

8

Early Stage

7

Mid Stage

3

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
8(44.4%)
Phase 2Efficacy & side effects
7(38.9%)
Phase 3Large-scale testing
3(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

72.2%

13 of 18 finished

Non-Completion Rate

27.8%

5 ended early

Currently Active

0

trials recruiting

Total Trials

18

all time

Status Distribution
Completed(13)
Terminated(5)

Detailed Status

Completed13
Terminated4
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
0
Success Rate
76.5%
Most Advanced
Phase 3

Trials by Phase

Phase 18 (44.4%)
Phase 27 (38.9%)
Phase 33 (16.7%)

Trials by Status

completed1372%
terminated422%
withdrawn16%

Recent Activity

0 active trials
Showing 5 of 18
completedphase_1

A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia

NCT01606436
completedphase_2

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

NCT00845026
terminatedphase_3

A Study of LY2140023 in Patients With Schizophrenia

NCT01307800
completedphase_1

A Study of Safety and Tolerability in Subjects With Schizophrenia

NCT01354353
completedphase_3

A Physical Dependence Study in Schizophrenia

NCT01452919
View all 18 trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT01606436Phase 1

A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia

Completed
NCT00845026Phase 2

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

Completed
NCT01307800Phase 3

A Study of LY2140023 in Patients With Schizophrenia

Terminated
NCT01354353Phase 1

A Study of Safety and Tolerability in Subjects With Schizophrenia

Completed
NCT01452919Phase 3

A Physical Dependence Study in Schizophrenia

Completed
NCT01052103Phase 2

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

Completed
NCT01328093Phase 3

A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

Terminated
NCT01475136Phase 1

A Study of LY2140023 in Hepatically-Impaired Participants

Completed
NCT01637142Phase 1

A Study of LY2140023 in Healthy Participants

Completed
NCT01609218Phase 1

A Study of LY2140023 in Healthy Participants

Completed
NCT01125358Phase 2

A Study in Schizophrenic Patients

Terminated
NCT01659177Phase 1

A Study of LY2140023 in Healthy Participants

Withdrawn
NCT00149292Phase 2

Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo

Completed
NCT01524237Phase 1

A Study of LY2979165 and LY2140023 in Healthy Volunteers

Completed
NCT01129674Phase 2

A Long-Term, Open-Label, Study on Schizophrenia

Terminated
NCT01086748Phase 2

A Study in Schizophrenia Patients

Completed
NCT01440478Phase 1

The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects

Completed
NCT00520923Phase 2

A Study for Patients With Schizophrenia

Completed

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18